The Pharmaceutical Research and Manufacturers of America (PhRMA) released yet another “report” in an obvious attempt to divert attention away from a problem of their own making: skyrocketing drug prices. They return once again to their standard playbook of pointing fingers and blaming everyone other than themselves to try to justify the dramatic increases in the prices of drugs, as they continue to make double-digit profit margins. The higher prices that drug manufacturers demand have caused immense hardships for many patients, their families, and the providers who care for them.

 

This most recent report is a brazen misrepresentation of the facts. The report conveniently fails to explain that, unlike drug manufacturers, hospitals are subject to fixed reimbursement amounts for the vast majority of the care they provide.

 

In fact, more than half of hospital payments are from public payers, including Medicare and Medicaid, which reimburse hospitals at a set amount far below their costs. Private payers also negotiate competitive rates with hospitals that often bundle the cost of drugs into a single, fixed reimbursement.
 

A 2015 study conducted by NORC at the University of Chicago for the AHA and the Federation of American Hospitals found that inpatient drug spending per admission increased 38.7 percent from 2013 to 2015. One of its primary findings was that continued growth in drug spending is a result of growing drug prices. And, more than 90 percent of hospital executives surveyed report that drug price increases have had a moderate or severe effect on their ability to predict and manage costs.


The U.S. health care system is in the midst of a prescription drug spending crisis that threatens both patient access to care and the ability of hospitals and health systems to deliver the highest quality of care. The Altarum Institute, which analyzes pricing data collected by the U.S. Bureau of Labor Statistics, identified price growth for prescription drugs as “easily the fastest growing category.”
 

To curb the skyrocketing prices of drugs, the AHA has put forth specific recommendations to further increase competition, transparency, access and value, while fostering innovation. It is time for drug companies to stop attacking others and come to the table with solutions on how to rein-in out-of-control drug prices for patients.

 

Ashley Thompson is AHA Senior Vice President of Public Policy Analysis and Development

Related News Articles

Headline
Price increases for over 1,200 drugs exceeded inflation between July 2021 and July 2022, including many drugs used to treat cancer and other chronic conditions…
Headline
The Centers for Medicare & Medicaid Services yesterday released premium and cost-sharing information for Medicare Advantage and Part D prescription drug…
Headline
In a study reported this week in JAMA Network Open, researchers found no association between a drug’s list price and research and development costs. The study…
Headline
The Consumer Price Index has climbed 8.6% over the past 12 months before seasonal adjustment, the fastest increase in over 40 years, the Bureau of Labor…
Headline
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA. Median…
Headline
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement…